Library
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
4 May 2024. doid: 10.1016/j.vaccine.2024.04.059
Cárdenas V, Le Gars M, Truyers C, Ruiz-Guiñazú J, Struyf F, Colfer A, Bonten M, Borobia A, Reisinger EC, Kamerling IMC, Douoguih M, Sadoff J
View publicationA single dose of Ad26.COV2.S is well-tolerated and effective in preventing moderate-to-severe disease outcomes due to COVID-19. We evaluated the impact of dose level, number of doses, and dose interval on immunogenicity, reactogenicity, and safety of Ad26.COV2.S in adults. Anamnestic responses were also explored.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
